A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

NCT Number	NCT06876662
Lead Sponsor	Eli Lilly and Company
Conditions	Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Enrollment	279 participants
Start Date	2025-05-20
Primary Completion	2030-05 (estimated)
Study Completion	2032-12 (estimated)
Updated on ClinicalTrials.gov	2026-03-02